Osteoprotegerin (OPG) in Induced Chronic Obstructive Pulmonary Disease (COPD) Sputum

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

72 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-01-31

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of OPG level as disease markers has also been reported. It has been showed that patients with coronary artery disease had higher serum OPG levels than healthy volunteers. Moreover, serum OPG levels correlate with the number of stenotic coronary arteries

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Markers for Chronic Obstructive Pulmonary Disease (COPD)

NCT00180622

Healthy Non-smokers Current Smokers COPD Patients

WITHDRAWN

Genomic/ Proteomic/ Metabonomic Profiling in Chronic Obstructive Pulmonary Disease (COPD)

NCT00655694

Pulmonary Disease, Chronic Obstructive

WITHDRAWN

Serum Surfactant Protein-D as Predictor of Disease Severity in Hospitalized COPD Patients

NCT07154953

COPD

NOT_YET_RECRUITING

Clinical Assessment of Patients With Chronic Obstructive Pulmonary Disease (COPD) and/or Chronic Heart Failure (CHF)

NCT01114386

COPD Heart Failure, Congestive

COMPLETED

General Practice Quality Assurance Project. Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment

NCT00319813

Pulmonary Disease, Chronic Obstructive

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Osteoprotegerin (OPG) is a secreted glycoprotein containing 401 amino acids. It is a member of the tumour necrosis factor (TNF) receptor superfamily. It was firstly discovered as a protein regulating bone metabolism, inhibiting osteoclastogenesis, consequently, inhibiting bone resorption OPG is detected in lung using Northern blot analysis. It is likely that OPG would contribute to the pathogenesis of COPD and could be an effective disease marker of the disease

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

* Healthy non-smokers

* Age \<35 years (younger group)
* Aged matched to COPD patients (older group)
* Normal spirometry
* Subjects are able to give informed consent
* Healthy smokers

* Age \<35 years (younger group)
* Aged matched to COPD patients (older group)
* Normal spirometry
* Subjects are able to give informed consent Stable COPD patients: Stage I-IV according to the GOLD guidelines (3), (9)
* Current and/or ex-smokers with no less than 10 pack-year smoking history
* The subjects are able to give informed consent COPD patients with acute exacerbation: Stage I-IV according to the GOLD guidelines (3), (9)
* Exacerbation of COPD defined as "an event in the natural course of the disease characterised by a change in the patient's baseline dyspnoea, cough and/or sputum beyond day to day variability sufficient to warrant a change in management" (9)
* Current and/or ex-smokers with no less than 10 pack-year smoking history
* The subjects are able to give informed consent Asthma patients
* Patients diagnosed with asthma
* The subjects are able to give informed consent Bronchiectasis patients
* Patients with CT-confirmed bronchiectasis
* The subjects are able to give informed consent Cystic fibrosis patients
* Patients diagnosed with cystic fibrosis
* The subjects are able to give informed consent

Exclusion Criteria

* Healthy non-smokers and smokers

* Upper respiratory infection within the last 4 weeks.
* Subjects who have received research medication within the previous one month.
* Subjects unable to give informed consent.
* Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study Stable COPD patients
* Patients who have had an exacerbation which required treatment with oral steroids during the last 2 months prior to the visit
* Upper respiratory infection within the last 4 weeks
* Subjects who have received research medication within the previous one month
* Subjects unable to give informed consent
* Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study COPD patients with acute exacerbation
* Subjects who have received research medication within the previous one month
* Subjects unable to give informed consent
* Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study Asthma
* Upper respiratory infection within the last 4 weeks
* Subjects who have received research medication within the previous one month
* Subjects unable to give informed consent.
* Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study.
* Bronchiectasis and cystic fibrosis

* Subjects who have received research medication within the previous one month.
* Subjects unable to give informed consent.
* Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study.

Minimum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes